Dupilumab, an IL‐4R receptor inhibitor, is the first biologic agent targeting the IL‐4 and IL‐13 signaling pathways, demonstrating favorable efficacy and safety across diverse populations and establishing itself as a critical treatment option for AD.16, 349. Here, IL13 is linked to Alzheimer disease.